These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
684 related articles for article (PubMed ID: 28970116)
1. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis. Das P; Paik D; Naskar K; Chakraborti T Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116 [TBL] [Abstract][Full Text] [Related]
2. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Choudhury R; Das P; De T; Chakraborti T Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis. Thakur A; Kaur H; Kaur S Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605 [TBL] [Abstract][Full Text] [Related]
4. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice. Thakur A; Kaur H; Kaur S Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis. Thakur A; Kaur H; Kaur S Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859 [TBL] [Abstract][Full Text] [Related]
6. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S; Ravindran R; Ali N Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029 [TBL] [Abstract][Full Text] [Related]
7. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate. Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653 [TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Nagill R; Kaur S Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Ravindran R; Maji M; Ali N Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194 [TBL] [Abstract][Full Text] [Related]
10. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis. Kaur H; Thakur A; Kaur S Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543 [TBL] [Abstract][Full Text] [Related]
11. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Kaur J; Kaur T; Kaur S Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477 [TBL] [Abstract][Full Text] [Related]
13. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700 [TBL] [Abstract][Full Text] [Related]
14. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980 [TBL] [Abstract][Full Text] [Related]
15. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
16. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine. Bhowmick S; Ravindran R; Ali N BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931 [TBL] [Abstract][Full Text] [Related]
17. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. Ravindran R; Bhowmick S; Das A; Ali N BMC Microbiol; 2010 Jun; 10():181. PubMed ID: 20576102 [TBL] [Abstract][Full Text] [Related]
18. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. Bhowmick S; Mazumdar T; Sinha R; Ali N J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373 [TBL] [Abstract][Full Text] [Related]
19. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. Mazumder S; Maji M; Ali N PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029 [TBL] [Abstract][Full Text] [Related]
20. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]